Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Revelation Biosciences Inc

REVB ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.98

▲ +5.13%

Market Cap $3.89M · Vol 777

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.89M

Micro Cap

Div Yield

N/A

EPS Growth

+78.35%

YoY

RSI (14)

46.59

Momentum

Beta

-0.10

vs Market

52W High

$6.72

86.15% below

52W Low

$0.89

4.54% above

Volume

777

Avg 3.62K

P/B

0.14

Price-to-book

ROE

N/A

Return on equity

Free Float

87.66%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Revelation Biosciences Inc (REVB) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does REVB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.40%

-10.27%

-0.19%

-17.81%

YTD

-69.43%

-84.12%

-99.97%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-8,913,650.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-97.93% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.14
P/FCF	N/A
EPS Growth	+78.35%
Outstanding Shares	3.98M

Technical Indicators

50-Day SMA	$1.05
200-Day SMA	$1.60
RSI (14)	46.59
Beta	-0.10
52-Week High	$6.72
52-Week Low	$0.89

Volume Today	777
Avg Daily Volume (30D)	3.62K
Relative Volume	0.21x
Volatility (10D)	52.39
Volatility (30D)	63.29
Free Float	87.66%

Analyst Consensus

BUY

Current Price $0.98

Mean Target $17.75

52W Low$0.89 52W High$6.72

Current

Target

$0.89 $6.72

Current Analyst target

+1,714.74% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00WH4GC08

ISINUS76135L8046

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.59% ONC BeOne Medicines AG +4.23% 068270.KS Celltrion, Inc. +1.11% MEDP Medpace Holdings, Inc. +1.94% ABVX Abivax SA -1.51%

Company Profile

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.